Share This Author
Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial.
It is concluded that MRD status after the second consolidation may be the best timing for treatment choice, and risk-directed risk stratification treatment may improve the outcome of t(8;21) AML in CR1.
Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study.
Unmanipulated haploidentical HSCT achieves outcomes similar to those of ISD HSCT for AML patients in CR1, and was demonstrated to be a valid alternative as postremission treatment of intermediate- or high-risk AMl patients inCR1 lacking an identical donor.
Long‐term follow‐up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia
A new strategy was developed for HLA‐mismatched/haploidentical transplantation from family donors without in vitro T cell depletion (TCD) for patients who require allogeneic hematopoietic stem cell transplantation (allo‐HSCT).
Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: a randomized, controlled…
An open-label, randomized phase II clinical study to assess the outcome of MSC coinfusion during haploidentical hematopoietic stem cell transplantation and found that within 100 days, the time to a platelet concentration of >50 × 10(9) cells/L was markedly faster in the treatment group compared with the control group.
Who is the best donor for a related HLA haplotype-mismatched transplant?
The data indicate which HLA haplotype-mismatched related donors are associated with the best transplant outcomes in persons with hematological neoplasms.
Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome
It is shown that tumor cell pyroptosis triggers CRS during CAR T cell therapy, and the quantity of perforin/granzyme B used by CAR T cells rather than existing CD8+ T cells is critical forCAR T cells to induce target cell pyproptosis.
Haploidentical versus Matched-Sibling Transplant in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia: A Biologically Phase III Randomized Study
Haploidentical HSCT achieves outcomes similar to those of MSD-HSCT for Philadelphia-negative high-risk ALL patients in CR1, suggesting that such transplantation could be a valid alternative as post-remission treatment for high- risk ALL patientsin CR1 lacking an identical donor.
Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia
It is indicated that relapse rate can be reduced and DFS may be improved in Ph’+ ALL patients with imatinib maintenance therapy after HCT and BCR-ABL monitoring by qRT-PCR can guide maintenance therapy withImatinib including initiation time and treatment duration after allo-HCT.
Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a…
For pre-MRD-positive AML patients, haplo-SCT was associated with lower incidence of relapse and better survival, suggesting a stronger anti-leukemia effect.